Adds Significant Financial and Healthcare Expertise; Expands Board from Four Members to Seven
Columbia, MD – (December 9, 2013) – ACell, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced that it has nearly doubled the size of its Board of Directors with the appointment of three members. The additions of Jon T. Tremmel, Steven P. Mullins and James D’Orta, M.D. increase the number of directors from four to seven.
Jon T. Tremmel held several senior leadership positions with Medtronic, Inc. until his retirement in April 2007, including serving as former president of several Divisions: Neurological, Physio-Control, Tachyarrhythmia Management and Interventional Vascular. He currently serves on the boards of medical device companies Cyberonics, Inc., EnteroMedics, Inc. and Flowonix Medical Incorporated.
Steven P. Mullins is currently the Chief Financial Officer (CFO) of KZ0 Innovations, Inc., President of SPM Consulting, and performs financial consulting services to a number of other companies on a part-time basis. He was formerly the CFO of InteliData Technologies Corporation.
James D’Orta, M.D. is a physician and entrepreneur who recently served as the Chairman and Chief Executive Officer (CEO) of Consumer Health Services, Inc., which was acquired by Walgreen Company in 2013. He was formerly an investor, medical advisor and member of the board of directors to Minute Clinic, which was acquired by CVS, Inc., and founder and CEO of LifeLink MD, which was acquired by Medtronic, Inc.
John J. McDonnell, Jr., Chairman of the Board of Directors, said, “We are pleased to add such significant financial and operational leadership as well as deep healthcare expertise to our Board. Jon, Steven and James each bring with them unique qualifications managing leading healthcare organizations that we believe that will help guide ACell toward continued growth and leadership in the regenerative medicine arena. We welcome our newest directors and look forward to their contributions to the strategic direction of the Company.”
Jim DeFrancesco, Chief Executive Officer and Director, said, “ACell has a significant opportunity to further expand our business across the complex wound management and soft surgical tissue repair markets. Jon, Steven and James add a wealth of experience that will allow us to further hone our strategy to accomplish that growth. I look forward to working with them over the next several years to bring our innovative solutions to a wider numbers of patients and physicians.”
With their addition to the board, Dr. D’Orta and Mullins become members of the Audit Committee and Nominating and Corporate Governance Committee, with Mullins chairing the Audit Committee and D’Orta chairing the Nominating and Corporate Governance Committee. Tremmel joins the Audit Committee and Compensation Committee, which is chaired by Magnus Moliteus.
ACell, Inc. offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix products to repair and remodel damaged tissues in a broad range of applications. Its patented MatriStem ECM medical devices maintain and support a healing environment through constructive remodeling and are available in particle and sheet forms for the treatment of acute wounds and various surgical procedures. For more information, visit www.acell.com.
About Jon T. Tremmel
Until his retirement in April 2007, Mr. Tremmel held several senior leadership positions with Medtronic, Inc. He served as President of Medtronic’s Neurological Division from March 2003 until 2007, President of Medtronic’s Physio-Control Division from May 2001 until March 2003, and President of Medtronic’s Tachyarrhythmia Management and Interventional Vascular Divisions between 1992 and 2001. Prior to 1992, he served in various positions of increasing responsibility at Medtronic after joining the company in 1978. Mr. Tremmel currently serves on several boards including: Cyberonics, Inc. a publicly traded company developing implantable products for treating drug refractory epilepsy; EnteroMedics, Inc., a publicly traded company developing a neurostimulation device for the treatment of obesity, and Flowonix Medical Incorporated, a privately-held company developing implantable pumps for chronic pain.
About Steven P. Mullins
Mr. Mullins has been the Chief Financial Officer of KZ0 Innovations, Inc., a provider of secure, social collaboration video software, since 2008. Mr. Mullins also serves as the President of SPM Consulting, a consulting firm for data-mining and database management marketing. From 1997 to 2002, Mr. Mullins worked at InteliData Technologies Corporation, a NASDAQ-traded company, where he served as Chief Financial Officer. Mr. Mullins is currently a member of the Board of Visitors of George Mason University, where he serves as Chairman of the Audit Committee, and previously, as Vice-Chairman of the Finance and Land Use Committee.
About James D’Orta, M.D.
Dr. D’Orta is a physician and entrepreneur and recently served as the Chairman and Chief Executive Officer of Consumer Health Services, Inc., which was acquired by Walgreen Company in 2013. From 2003 to 2006 he was an investor, medical advisor and member of the board of directors to Minute Clinic, which was acquired by CVS, Inc. Prior to that, Dr. D’Orta was the founder and Chief Executive Officer of LifeLink MD, a national physician service and medical device oversight provider acquired by Medtronic Inc., beginning in 1999. Dr. D’Orta has served as a director for CareFirst, Inc. since 2007 and as a director for the Maryland Emergency Medicine Network at the University of Maryland Faculty Practice since 2003. He has held Director positions at Georgetown University Hospital and the Board of Visitors at Johns Hopkins University School of Medicine. He currently holds faculty positions in Emergency Medicine at George Washington University and the University of Maryland School of Medicine.
ACell, Inc. is a leading developer, manufacturer and marketer of next-generation regenerative medicine products. Its products are cleared for a variety of indications and are marketed under the brand name “MatriStem.” A privately held Company, Acell produces MatriStem in its manufacturing facilities and markets its products to physicians in the U.S. through a national direct sales force. For more information, call (800) 826-2926 or visit www.acell.com.
MatriStem Products consist of porcine-derived extracellular matrix (ECM) that maintain and support a healing environment through constructive remodeling, and are available in particle and sheet forms by prescription only. These devices, trademarked as MatriStem, are appropriate for acute wounds, chronic wounds and various surgical procedures. All MatriStem devices are made in the USA. Refer to IFU supplied with each device for indications, contraindications, and precautions.Return to News